Key facts: Novo Nordisk, Eli Lilly to Cut GLP-1 Drug Prices; Novo Commits to Terms
I'm PortAI, I can summarize articles.
Novo Nordisk and Eli Lilly have agreed to lower the prices of their GLP-1 weight-loss drugs for Medicare and Medicaid programs, along with cash-paying patients.1Novo Nordisk has committed to the U.S. government's most-favored-nation pricing terms for its drugs, aligning with four other pharmaceutical companies in this agreement.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments